Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
日本第二型糖尿病且合併肥胖或過重患者中,每週一次 tirzepatide 的療效與安全性:SURMOUNT-2 試驗的亞族群分析
Diabetes Obes Metab 2025-06-09
Drug-Related Visual Blurring: Findings from the U.S. Food and Drug Administration Adverse Event Reporting System Database.
藥物相關視覺模糊:來自美國食品藥物管理局不良事件通報系統資料庫的發現
Eur J Pharmacol 2025-06-09
Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD.
第二型糖尿病合併MASLD患者中,不同抗糖尿病藥物類別對肝相關事件風險的影響
Clin Gastroenterol Hepatol 2025-06-09
Anti-CGRP Monoclonal Antibodies Counteract Establishment of Food Aversive Memories and Chemotherapy-induced Anorexia and Weight Loss.
Anti-CGRP 單株抗體可對抗食物厭惡記憶的建立及化療引起的厭食與體重減輕
Pharmacol Res 2025-06-09
Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery.
pH、緩衝液、莫耳濃度與溫度對 semaglutide 溶液狀態降解的影響:利用 LC-HRMS 的胜肽藥物傳遞前製劑評估流程
Eur J Pharm Biopharm 2025-06-09
External control arm with real-world Data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.
以真實世界數據建立外部對照組,評估 semaglutide 對第二型糖尿病患者慢性腎臟病風險的影響
Expert Opin Pharmacother 2025-06-09
Homeostatic Appetite and Hedonic Hunger 13 Years After Roux-en-Y Gastric Bypass: Potential Associations and Predictive Value in Determining Long-Term Weight Loss Outcomes.
Roux-en-Y 胃繞道手術後 13 年的恆定性食慾與享樂性飢餓:其潛在關聯性及對長期體重減輕結果的預測價值
Obes Surg 2025-06-09
Association of GLP-1 Receptor Agonists with Liver-Related Outcomes and All-Cause Mortality in Patients with Harmful Alcohol Use: A Target Trial Emulation Study.
GLP-1 受體促效劑與有害酒精使用患者肝臟相關結局及全因死亡率之關聯:一項目標試驗模擬研究
Am J Gastroenterol 2025-06-09